

SARS-CoV2 antigeen Diasorin

Validatie Microvida

19-01-2021

Indeling

1. Technische validatie.
2. In house klinische validatie: Microvida locatie ETZ.
3. Teststraat klinische validatie: GGD teststraat Tilburg.

Technische validatie: methode

- Diluting a cell cultured SARS-CoV-2 strain:
 - (SARS hCoV-19/Netherlands/NoordBrabant_10003/2020 SARS-CoV-2)
 - median tissue cultured infectious dose (TCID₅₀) of 5.62×10^7 per mL in 10-fold series ($10^{-1} - 10^{-8}$)
 - In triplicate testing of both SARS-CoV2 Antigen assay using the following volumes of virus stock.
 - Diasorin antigen assay and Roche antigen assay performed on soaked nasopharynx swabs
 - Diasorin antigen assay performed on 1000 uL of the dilution series added to 1000 uL lysis buffer.
 - Diasorin antigen assay performed on 350 uL of the dilution series added to 1000 uL lysis buffer.
 - Roche antigen assay performed on 350 uL of the dilution series added to 320 uL of RRA extraction buffer.
 - Duplicate qRT-PCR (Allinity, abbott) on 500 µl of the dilution series, qRT-PCR was performed in duplex, the Ct-value is the mean

Technische validatie: resultaten

- SARS-CoV-2 Ag assays performed in triplicate on nasopharynx **swabs** soaked in each dilution.

Dilution step	TCID50/ml	Ct-value qRT-PCR*	Diasorin antigen (RLU signal range)	Roche antigen
10 ⁻¹	5,62E+06	10.23	3/3 (>100000)	3/3
10 ⁻²	5,62E+05	13.17	3/3 (14436-16112)	3/3
10 ⁻³	5,62E+04	16.75	3/3 (2247-2437)	3/3
10 ⁻⁴	5,62E+03	20.20	3/3 (328-272)	3/3
10 ⁻⁵	5,62E+02	24.33	0/3 (86-89)	0/3
10 ⁻⁶	5,62E+01	28.02	0/3 (53-62)	0/3
10 ⁻⁷	5,62E+00	31.21	0/3 (52-60)	0/3
10 ⁻⁸	5,62E-01	35.32	0/3 (56-65)	0/3
blanc	0	>50	0/3	0/3

Technische validatie: resultaten

- SARS-CoV-2 Ag assays performed in triplicate on each dilution using two different volumes.

Dilution step	TCID50/ml	Ct-value qRT-PCR*	Diasorin (RLU signal range)		Roche
			1000 uL	350 uL	
10 ⁻¹	5,62E+06	10.23	3/3 (>100000)	3/3 (>100000)	3/3
10 ⁻²	5,62E+05	13.17	3/3 (20926-22301)	3/3 (>100000)	3/3
10 ⁻³	5,62E+04	16.75	3/3 (10753-12422)	3/3 (10753-12422)	3/3
10 ⁻⁴	5,62E+03	20.20	3/3 (2319-2614)	3/3 (1524-1700)	3/3
10 ⁻⁵	5,62E+02	24.33	3/3 (297-352)	1/3 (173-232)	3/3
10 ⁻⁶	5,62E+01	28.02	0/3 (64-82)	0/3 (54-67)	0/3
10 ⁻⁷	5,62E+00	31.21	0/3 (31-40)	0/3 (47-58)	0/3
10 ⁻⁸	5,62E-01	35.32	0/3 (34-40)	0/3 (39-45)	0/3
blanc	0	>50	0/3	0/3	0/3

In house klinische validatie: Methode

- Persons presenting at the Municipal Health Service (GGD) test service received a combined oro-/nasopharyngeal swabs.
 - Suspended in 3mL GLY-medium
 - qRT-PCR performed on 500uL uGLY-medium (allinity, abbott)
 - Diasoring antigen assay performed on 1000uL GLY-medium suspended in 1000uL lysis buffer
 - Total suspension volume of original swab is 3mL GLY + 1000uL lysis buffer -> **1:4**.
 - **Inactivation period of 2-hours.**
- Cut-off positive samples of Diasorin antigen Assay: **200**.
- Comparing sensitivitiy specificity of Diasorin antigen assay with PCR:
 - Stratified for Ct-value:
 - Ct-value < 30
 - Ct-value < 25

In house klinische validatie: Resultaten

- A total of n=248 samples were included:
 - N=74 (29,9%) positive qRT-PCR for SARS-CoV-2 RNA.
 - N=174 (70,1%) negative qRT-PCR for SARS-CoV-2 RNA.

		qRT-PCR result		
		positive		negative
DAA	positive	54		0
		Ct > 30	Ct: 25-30	
		0	1	53
	negative	20		174
		Ct > 30	Ct: 25-30	
		11	5	4

Specificity:

- 100%

Sensitivity:


- Overall: 72,9%
- Ct-value < 30: 85,7%
- Ct-value < 25: 92,9%.

In house klinische validatie: Resultaten

- Distribution of RLU results of the DAA of qRT-PCR positive and negative samples.


RLU signal in DAA	qRT-PCR result	
	positive	negative
<22	11	156
22-40	1	17
40-60	2	1
60-80	1	0
80-100	1	0
100-120	0	0
120-140	1	0
140-160	0	0
160-180	3	0
180-200	0	0

Current cut-off



In house klinische validatie: Resultaten

- Relation between the 10log transformed RLU values of the DAA and Ct-values of the qRT-PCR.



Teststraat klinische validatie: methode



- On location testing for COVID-19 using Diasorin antigen assay performed on the LIAISON XL.
- Two alterations in the procedure:
 - Combined oro-/nasopharyngeal swabs direct in 500uL GLY-medium + 500 uL lysis buffer. (according to manufacturers instruction)
 - Dilution swab **in 1mL instead of 4mL.**
 - Inactivation period of **30 minutes instead of 2 hours.**

Teststraat klinische validatie: methode



On site clinical validation: comparing PCR to Diasorin antigen test:

- After 30 minutes inactivation.
- After 2 hours inactivation. (subset)

Diluting samples 1:1 in GLY medium to assess the effect of sample dilution.

Teststraat klinische validatie: resultaten

- A total of n=823 samples were included:
 - N= 90 (10,9%) positive qRT-PCR for SARS-CoV-2 RNA.
 - N= 733 (89,1%) negative qRT-PCR for SARS-CoV-2 RNA.
- After 30 minutes inactivation and using cut-off 200.

		qRT-PCR result		
		positive		negative
DAA	positive	58		23
		Ct > 30	Ct: 25-30	
		0	4	54
	negative	32		710
		Ct > 30	Ct: 25-30	
		19	10	3


Specificity:

- 96,7%

Sensitivity:

- Overall: 64,4%
- Ct-value < 30: 81,7%
- Ct-value < 25: 94,7%.

Teststraat klinische validatie: resultaten



VS

RLU signal in DAA	qRT-PCR result	
	positive	negative
<22	11	156
22-40	1	17
40-60	2	1
60-80	1	0
80-100	1	0
100-120	0	0
120-140	1	0
140-160	0	0
160-180	3	0
180-200	0	0

Teststraat klinische validatie: resultaten

- Increasing the Cut-off: 200 -> 300 -> 400.

200

Specificity:

- 96,7%

Sensitivity:

- Overall: 64,4%
- Ct-value < 30: 81,7%
- Ct-value < 25: 94,7%.

300

Specificity:

- 98,2%

Sensitivity:

- Overall: 63,3%
- Ct-value < 30: 80,3%
- Ct-value < 25: 93,0%.

400

Specificity:



- 99,2%

Sensitivity:

- Overall: 62,2%
- Ct-value < 30: 78,9%
- Ct-value < 25: 93,0%.


Resultaten: verschil locatie ETZ en Teststraat

- Effect inactivation duration on measured RLU:
- A total of n=558 samples were included:
 - N= 56 (10,0%) positive qRT-PCR for SARS-CoV-2 RNA.
 - N= 502 (90,0%) negative qRT-PCR for SARS-CoV-2 RNA.



Resultaten: verschil locatie ETZ en Teststraat

- Effect sample dilution on measured RLU.



Discussie: heden in gebruik

- Currently
 - we are using a cut-off of 400.
 - To optimize specificity
 - Samples are inactivated for 30 minutes
 - Results are faster available
 - No clear benefit of increasing activation time given the current cut-off